From bench to bedside, clinical trials translate basic scientific findings into therapeutic interventions and increase understanding of disease processes. In fact, clinical research is the cornerstone of all advances in medicine.
The Polyclinic supports the value of research and has been offering our patients access to clinical trials for over six years. Many of these trials have involved therapies that have since been FDA approved and are now available treatment options. Many others have been recognized in respected scientific publications and provided invaluable information.
Successful Celiac Disease Trial
Most recently, Dr. Craig Pepin’s contributions as an investigator on a multi-center Phase 2B celiac disease trial were acknowledged in Gastroenterology (2017; 152:787-798). This trial studied the effect of different dose levels of latiglutenase administered for 12 weeks on reducing mucosal injury as well as celiac disease symptom frequency and severity.
Celiac disease is a serious autoimmune disorder that affects an estimated one in 100 people worldwide. Left untreated, celiac disease can lead to additional serious health problems, including bone disorders, infertility, cancer and an increase in overall mortality. Currently the only treatment option is a strict lifelong exclusion of dietary gluten but even highly motivated patients may still experience inadvertent or background exposures to gluten. Thus, the continued need for development of non-dietary therapies for patients affected by celiac disease.
Trials such as the one conducted by Dr. Pepin are essential in seeing this realized and advancing patient care with improved treatment options. The study was a critical step forward in the mission all healthcare providers share - to improve the lives of our patients. Together with the patients who participate in trials, The Polyclinic is helping improve care; both now and for generations to come.